JP2004513093A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004513093A5 JP2004513093A5 JP2002535640A JP2002535640A JP2004513093A5 JP 2004513093 A5 JP2004513093 A5 JP 2004513093A5 JP 2002535640 A JP2002535640 A JP 2002535640A JP 2002535640 A JP2002535640 A JP 2002535640A JP 2004513093 A5 JP2004513093 A5 JP 2004513093A5
- Authority
- JP
- Japan
- Prior art keywords
- glass
- component
- subject
- delivering
- bioactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011521 glass Substances 0.000 claims 5
- 230000000975 bioactive effect Effects 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000005365 phosphate glass Substances 0.000 claims 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims 2
- 239000012867 bioactive agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/028244 WO2002032402A1 (en) | 2000-10-13 | 2000-10-13 | Composition and method for stable injectable liquids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003383800A Division JP4027881B2 (ja) | 2003-11-13 | 2003-11-13 | 安定注射液用の組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004513093A JP2004513093A (ja) | 2004-04-30 |
| JP2004513093A5 true JP2004513093A5 (OSRAM) | 2005-08-04 |
Family
ID=21741883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002535640A Withdrawn JP2004513093A (ja) | 2000-10-13 | 2000-10-13 | 安定注射液用の組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1328255A1 (OSRAM) |
| JP (1) | JP2004513093A (OSRAM) |
| KR (1) | KR20030096224A (OSRAM) |
| CN (1) | CN100339066C (OSRAM) |
| AU (2) | AU1198601A (OSRAM) |
| CA (2) | CA2424656C (OSRAM) |
| ES (1) | ES2337252T3 (OSRAM) |
| MX (1) | MXPA03003236A (OSRAM) |
| NO (1) | NO20031706D0 (OSRAM) |
| PL (1) | PL360052A1 (OSRAM) |
| PT (1) | PT1452171E (OSRAM) |
| WO (1) | WO2002032402A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003301654A1 (en) * | 2002-10-22 | 2004-05-13 | Dainippon Pharmaceutical Co., Ltd. | Stabilized composition |
| JP2007001865A (ja) * | 2003-09-16 | 2007-01-11 | Ltt Bio-Pharma Co Ltd | 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤 |
| CA2562606A1 (en) | 2004-04-13 | 2005-10-27 | Cambridge Biostability Limited | Liquids containing suspended glass particles |
| GB0408199D0 (en) * | 2004-04-13 | 2004-05-19 | Cambridge Biostability Ltd | Liquids containing suspended sugar glass particles |
| GB2430880A (en) * | 2005-10-04 | 2007-04-11 | Cambridge Biostability Ltd | Pharmaceutical compositions stabilized in glassy particles |
| GB0523638D0 (en) * | 2005-11-21 | 2005-12-28 | Cambridge Biostability Ltd | Pharmaceutical device for the administration of substances to patients |
| US8946200B2 (en) | 2006-11-02 | 2015-02-03 | Southwest Research Institute | Pharmaceutically active nanosuspensions |
| CN101932317B (zh) * | 2008-01-18 | 2013-03-27 | 旭化成制药株式会社 | 稳定的药物组合物 |
| US8404850B2 (en) | 2008-03-13 | 2013-03-26 | Southwest Research Institute | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors |
| US8722706B2 (en) | 2008-08-15 | 2014-05-13 | Southwest Research Institute | Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts |
| US8309134B2 (en) | 2008-10-03 | 2012-11-13 | Southwest Research Institute | Modified calcium phosphate nanoparticle formation |
| WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
| WO2011007327A2 (en) | 2009-07-16 | 2011-01-20 | Koninklijke Philips Electronics N.V. | Suspension for therapeutic use and device for delivering said suspension |
| ES2362525B8 (es) | 2009-10-08 | 2013-01-03 | Azurebio, S.L. | Formulación de medicamentos en forma de agujas percutaneas penetrantes. |
| US9028873B2 (en) | 2010-02-08 | 2015-05-12 | Southwest Research Institute | Nanoparticles for drug delivery to the central nervous system |
| WO2015147001A1 (ja) | 2014-03-24 | 2015-10-01 | セイコーエプソン株式会社 | テープ印刷装置およびテープ印刷システム |
| US10744098B2 (en) * | 2014-03-27 | 2020-08-18 | Novartis Ag | Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR78151B (OSRAM) * | 1982-04-05 | 1984-09-26 | Alcon Lab Inc | |
| US5518731A (en) * | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
| AU3924193A (en) * | 1992-03-19 | 1993-10-21 | Allergan, Inc. | Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid |
| GB9705588D0 (en) * | 1997-03-18 | 1997-05-07 | Anglia Research Foundation | Stable particle in liquid formulations |
| US6190701B1 (en) * | 1999-03-17 | 2001-02-20 | Peter M. Ronai | Composition and method for stable injectable liquids |
-
2000
- 2000-10-13 AU AU1198601A patent/AU1198601A/xx active Pending
- 2000-10-13 KR KR10-2003-7004941A patent/KR20030096224A/ko not_active Ceased
- 2000-10-13 WO PCT/US2000/028244 patent/WO2002032402A1/en not_active Ceased
- 2000-10-13 JP JP2002535640A patent/JP2004513093A/ja not_active Withdrawn
- 2000-10-13 CN CNB008199655A patent/CN100339066C/zh not_active Expired - Fee Related
- 2000-10-13 AU AU2001211986A patent/AU2001211986B2/en not_active Ceased
- 2000-10-13 EP EP00973483A patent/EP1328255A1/en not_active Withdrawn
- 2000-10-13 PT PT04013422T patent/PT1452171E/pt unknown
- 2000-10-13 CA CA2424656A patent/CA2424656C/en not_active Expired - Lifetime
- 2000-10-13 MX MXPA03003236A patent/MXPA03003236A/es active IP Right Grant
- 2000-10-13 CA CA2689856A patent/CA2689856C/en not_active Expired - Lifetime
- 2000-10-13 ES ES04013422T patent/ES2337252T3/es not_active Expired - Lifetime
- 2000-10-13 PL PL00360052A patent/PL360052A1/xx unknown
-
2003
- 2003-04-11 NO NO20031706A patent/NO20031706D0/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004513093A5 (OSRAM) | ||
| ES2569949T3 (es) | Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina | |
| WO2001058474A3 (en) | Microencapsulation and sustained release of biologically active agent | |
| CA2323680A1 (en) | Orally disintegrable tablets | |
| CA2281473A1 (en) | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same | |
| WO2002045684A3 (en) | Rapidly dispersing pharmaceutical composition comprising effervescent agents | |
| AU2003304237A1 (en) | Gel-stabilized nanoparticulate active agent compositions | |
| DK1429731T3 (da) | Nanopartikelformuleringer indeholdende insulin | |
| CY1107752T1 (el) | Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης | |
| IT1246350B (it) | Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili | |
| WO2002049676A3 (en) | Compositions containing inclusion complexes | |
| PL342162A1 (en) | Galenic form for oral administration of either immediate or prolonged drug release containing an absorption enhancing agent and application of such absorption enhancing agent | |
| BG102228A (en) | Medicamentous form with controlled release of slightly soluble medicamentous substances | |
| EP2298279A3 (en) | Pharmaceutical compositions for inhalation | |
| NZ533062A (en) | Formulation and dosage form for the controlled delivery of therapeutic agents | |
| EP1790340A3 (en) | Combination chemotherapy | |
| WO2005007185A3 (de) | Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa) | |
| TNSN99173A1 (fr) | Livraison d'agent actif sous forme de poudre seche | |
| ATE521343T1 (de) | Im mund zerfallende zusammensetzungen von rasagilin | |
| WO2000010533A3 (en) | Compositions and methods for treating intracellular infections | |
| SI1561460T1 (sl) | Nanodelci za aplikacijo uäśinkovin, postopek za pripravo teh delcev in sestavek, ki jih vsebuje | |
| HUP0300221A3 (en) | Use of oltipraz as an antifibrotic and anticirrhotic agent in the liver for producing pharmaceutical compositions and pharmaceutical compositions containing oltipraz and process for producing them | |
| EP0787498A3 (en) | Therapeutic human albumin having a low aluminium binding capacity | |
| WO2001085188A3 (en) | Use of echinacea as a hematinic agent | |
| WO2006058298A3 (en) | A method of administering anti-angiogenic agents and a method of treating disease using same |